Stemline Therapeutics Inc (NASDAQ:STML) shares were up 5.1% during trading on Friday . The stock traded as high as $10.39 and last traded at $10.32, approximately 547,906 shares traded hands during mid-day trading. A decline of 11% from the average daily volume of 615,361 shares. The stock had previously closed at $9.81.
STML has been the subject of a number of recent analyst reports. ValuEngine cut Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, September 11th. Zacks Investment Research lowered Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 30th. BidaskClub upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Cowen restated a “buy” rating on shares of Stemline Therapeutics in a report on Wednesday, September 18th. Finally, HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Stemline Therapeutics in a research note on Monday, November 11th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Stemline Therapeutics currently has an average rating of “Buy” and an average price target of $22.57.
The stock’s 50-day moving average price is $10.04 and its 200-day moving average price is $12.30.
A number of large investors have recently bought and sold shares of STML. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Stemline Therapeutics by 51.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,297 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 1,466 shares during the period. Bank of Montreal Can acquired a new position in shares of Stemline Therapeutics during the second quarter valued at $52,000. Steward Partners Investment Advisory LLC acquired a new position in shares of Stemline Therapeutics during the second quarter valued at $67,000. Tower Research Capital LLC TRC boosted its holdings in Stemline Therapeutics by 364.4% in the third quarter. Tower Research Capital LLC TRC now owns 7,115 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 5,583 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in Stemline Therapeutics in the second quarter valued at about $104,000. 83.07% of the stock is currently owned by hedge funds and other institutional investors.
About Stemline Therapeutics (NASDAQ:STML)
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
See Also: Earnings Per Share
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.